Melanin-Concentrating Hormone Receptor 1 Market Growing at a CAGR of 4.2%

Melanin concentrating hormone receptor 1 (MCHR1) market is anticipated to grow at a considerable CAGR of 4.2% during the forecast period. The increasing global prevalence of obesity and associated metabolic disorders represents a primary driver for the growth of the Melanin-Concentrating Hormone Receptor 1 (MCHR1) market, particularly given its direct role in appetite regulation and energy homeostasis. According to the World Health Organization, in 2022, nearly 2.5 billion adults were overweight, including over 890 million living with obesity, with 1 in 8 individuals globally affected by obesity. This sharp rise, coupled with the fact that global adult obesity has more than doubled since 1990, highlights a significant unmet clinical need for novel pharmacological interventions targeting neurobiological pathways such as MCHR1. From a mechanistic standpoint, melanin-concentrating hormone (MCH) is known to stimulate food intake and promote fat accumulation, positioning MCHR1 antagonists as a promising therapeutic class for obesity management and related disorders. Consequently, pharmaceutical companies are increasingly investing in compounds such as ALB-127158, AZD-3857, and BI-186908 to address this expanding patient pool.

Browse the full report description of “Melanin Concentrating Hormone Receptor 1 Market Size, Share & Trends Analysis Report by Type (ALB-127158, AZ-13483342, AZD-3857, BI-186908, and Others), by Application (Obesity, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis, and Others), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/melanin-concentrating-hormone-receptor-1-market

The impact is even more pronounced in emerging economies such as India, where epidemiological transitions are accelerating disease burden. Government-backed surveys such as the National Family Health Survey (NFHS-5) indicate that obesity prevalence has risen to 6.4% among women and 4.0% among men, while broader estimates suggest over 135 million individuals in India are obese. Furthermore, obesity prevalence in certain urban populations ranges between 30% and 65%, reflecting rapid lifestyle changes and increasing sedentary behavior. This growing burden is strongly linked with comorbidities such as non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), and cardiovascular disorders, thereby expanding the therapeutic scope of MCHR1-targeted drugs beyond obesity alone. As healthcare systems and regulatory bodies prioritize non-communicable disease management, the demand for innovative, mechanism-based therapies such as MCHR1 antagonists is expected to accelerate, making obesity epidemiology a critical determinant in market sizing and long-term growth projections.

Innovation Leaders Transforming the Melanin-Concentrating Hormone Receptor 1 Market

The key players in the melanin-concentrating hormone receptor 1 market include AstraZeneca plc, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., among others. Companies operating in the Melanin-Concentrating Hormone Receptor 1 market are advancing innovation through the development of selective MCHR1 antagonists, enhanced receptor-targeting mechanisms, and improved pharmacokinetic profiles, enabling effective modulation of appetite regulation and metabolic pathways while supporting the growing demand for targeted therapies in obesity, inflammatory disorders, and related chronic conditions.

• In August 2021, Harmony Biosciences entered into a research collaboration, option, and licensing agreement with CiRC Biosciences to advance early-stage candidates, supporting the development of potential MCHR1-targeted cell therapies for treatment-resistant narcolepsy.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Fuel Cell Technology
  • By Power Capacity
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AstraZeneca plc, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Melanin-Concentrating Hormone Receptor 1 Market Report Segment

By Type

• ALB-127158
• AZ-13483342
• AZD-3857
• BI-186908
• Others

By Application

• Obesity
• Inflammatory Bowel Disease
• Non-Alcoholic Steatohepatitis
• Others

Global Melanin-Concentrating Hormone Receptor 1 Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/melanin-concentrating-hormone-receptor-1-market